ARTICLE | Clinical News
CPI-613: Phase II started
September 30, 2013 7:00 AM UTC
Cornerstone began an open-label, U.S. Phase II trial to evaluate IV CPI-613 given on days 1 and 4 for the first 3 weeks of a 4-week cycle in about 20 patients who have been unresponsive to previous th...